|Bid||310.75 x 800|
|Ask||310.70 x 900|
|Day's range||310.57 - 317.28|
|52-week range||203.13 - 323.61|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||24.42|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
BOSTON, November 09, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences:
BOSTON, November 04, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch "Power Forward" (www.PowerForwardTogether.com), an educational initiative aimed at raising awareness of APOL1-mediated kidney disease (AMKD), highlighting the importance of early diagnosis and genetic testing.
BOSTON, November 03, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts on the company’s portfolio of cystic fibrosis (CF) medicines will be presented in posters and oral presentations at this year’s North American Cystic Fibrosis Conference (NACFC), including studies demonstrating the clinical benefits and long-term safety of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor).